key: cord-0826180-tdwr5sl0
authors: Preziosa, Paolo; Rocca, Maria A.; Nozzolillo, Agostino; Moiola, Lucia; Filippi, Massimo
title: COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience
date: 2020-11-20
journal: J Neurol
DOI: 10.1007/s00415-020-10309-4
sha: 9c2b63b20b3935fdc7a0fb569c45058ecd076010
doc_id: 826180
cord_uid: tdwr5sl0

nan

Cladribine is a purine nucleoside analog that inhibits DNA synthesis and repair in highly dividing cells inducing B-and T-cell apoptosis [1] . Through a selective but transient depletion of these lymphocyte subsets [1, 5] , cladribine significantly reduces disease activity and disability progression in relapsing-remitting multiple sclerosis (RRMS) patients [2] [3] [4] .

The SARS-CoV-2 pandemic has raised several concerns regarding the use of immunosuppressants in RRMS patients [6] , since they are vulnerable to infections due to their disability and the use of drugs acting specifically on the immune system [7] .

However, the influence of cladribine on the risk of developing COVID-19 disease is still unclear. Only two case series with three RRMS patients reported no or mild COVID-19 disease [8] or moderate pneumonia [9] .

Here, we evaluated the prevalence and clinical features of COVID-19 disease among RRMS patients treated with cladribine in our center in Lombardy, Italy. From the whole MS population of our center, those treated with cladribine (Table 1 ) were asked if they had developed manifestations suggestive of COVID-19 disease up to August 25th 2020. Detailed demographic, clinical, and laboratoristic characteristics were collected.

Since the pandemic start, 2/56 (3.6%) RRMS treated with cladribine complained a symptomatology suggestive of COVID-19 disease.

The first RRMS patient is a 30-year-old male, with a short disease duration (1.4 years), mild disability (Expanded Disability Status Scale [EDSS] score = 1.5), and no comorbidities ( Table 2) . He started cladribine on January 10th 2020. One week later, he developed fever (< 37.5°), ageusia, cough, fatigue, sputum production, sore throat, nasal congestion, shortness of breath without desaturation, and conjunctivitis. Serology for SARS-CoV-2 was negative in May 2020. Blood examinations performed before and after COVID-19 disease were within normal limits, except for a mild lymphopenia (0.9*10^9/liter) after cladribine administration.

The second RRMS patient is a 40-year-old female with a disease duration of 13.4 years, moderate disability (EDSS = 3.5), and no comorbidities ( Table 2 ). She started cladribine on February 13th 2020 and underwent the second week of the first treatment course from March 5th 2020. On March 30th, she developed fever (< 37.8°), anosmia, ageusia, cough, fatigue, and bone/joint pain. Serology for SARS-CoV-2 performed in May 2020 was positive. Blood examinations both before and after COVID-19 disease were normal.

Both patients stayed at home, were telephone-monitored by their neurologists, and fully recovered within 2 weeks. Unfortunately, both patients did not perform nasal swabs during the symptomatic phase of COVID-19 disease.

In line with recent reports [8] [9] [10] [11] , only a minority of RRMS patients receiving cladribine (2/56, 3.6%) developed a mild and self-limiting COVID-19 disease. This prevalence was similar to that of the whole MS population of our center Although cladribine treatment is associated with peripheral lymphocyte depletion [5] , our findings are consistent with data from randomized-controlled trials [12] , showing that infections with cladribine are infrequent and, typically, self-limiting.

It is noteworthy that, in our cohort, COVID-19 disease occurred only in two RRMS patients close to treatment course and the possible nadir of selective immunosuppression. Accordingly, cladribine treatment could be safe during the COVID-19 pandemic. However, some precautions are needed during the first weeks after cladribine administration, when the risk of SARS-COV-2 infection could be higher due to transient immunosuppression. Further studies are necessary to evaluate whether cladribine could also prevent the cytokine storm associated with the most severe manifestations of COVID-19 disease [13] .

In conclusion, young RRMS patients treated with cladribine, without comorbidities and with transitory systemic immunosuppression, are likely to show a risk of COVID-19 infection and complications that are similar to the general population. 

Cladribine to treat relapsing forms of multiple sclerosis

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study

Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event

Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis

Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic

Disease-modifying therapies and infectious risks in multiple sclerosis

Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: two cases and implications for clinical practice

COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment

Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis

On behalf of the Italian Study Group on COVID-19 infection in multiple sclerosis. An Italian programme for COVID-19 infection in multiple sclerosis

Safety of cladribine tablets in the treatment of patients with multiple sclerosis: an integrated analysis

COVID-19 infection: the perspectives on immune responses